Interview with Michal Konstacky, MD at @Aerocrine
Aerocrine, a medical technology company focused on improving the treatment of patients with inflamed airways by identifying nitric oxide (NO) as a marker of inflammation. Aerocrine has HQ in Sweeden.
The founders of Aerocrine emerged from the highly prestigious Karolinska Institute in Sweden where they were the first to identify nitric oxide (NO) as a marker of inflammation. Aerocrine has taken this significant discovery from laboratory to listed company and is now established in some of the world’s largest markets. The company markets NIOX MINO. A highly reliable and effective tool to assist in the diagnosis and control of airways disease.